Pediatric Traumatic Brain Injury Consortium: Hypothermia

儿科创伤性脑损伤联盟:体温过低

基本信息

项目摘要

DESCRIPTION (provided by applicant): Despite preventative measures, traumatic brain injury (TBI) remains the leading cause of death and disability in children. While most pediatric treatment regimens for TBI to date are derived from adult studies, no therapeutic regimen has been particularly successful in improving outcome in children. There have been numerous laboratory studies utilizing moderate hypothermia (HYPO) (32-33¿C) in mature and immature animals, successful Phase II and III clinical studies in adult patients for 24 to 48 h after TBI, and a number of trials in children of HYPO following hypoxia-ischemic (HIE) brain injuries that have supported the efficacy of this intervention. The most recently published trial of treatment with HYPO for HIE within 6 hours showed significant improvement in outcome, particularly in mortality, as compared to severe disability. While the multi-center Phase III randomized controlled clinical trial (RCT) of moderate HYPO in adults was stopped early due to futility but not lack of efficacy, the secondary analysis did highlight that younger adult patients (< 40 y) tended toward improved outcome compared to older subjects. This finding along with a trend toward improved outcomes with early cooling (< 6 h) has resulted in a funded HYPO RCT specifically inclusive of patients ages 16- 45 y and early pre-hospital cooling that has recently begun. Based on the results from our Pilot Clinical Trial (PCT) utilizing moderate HYPO following severe TBI in children, the following application is for a multicenter Phase III RCT to determine whether induced early cooling (within 6 h) (32-33¿C) after severe TBI in children and maintained for 48 h will improve mortality at 3 mos post injury as compared to normothermia (37- 38¿C). The Secondary Hypotheses, again based on the analysis of the PCT, are that early HYPO after severe TBI in children and maintained for 48 h: 1) will improve global function as measured by the GOS/ GOS- Extended Pediatrics (GOS- E Peds) and neurocognitive status across the domains of intellectual development, learning and memory, and behavior at 6 and 12 mos after injury; 2) will be more effective in younger children < 6 y compared to older children, > 6y, and 3) will lessen intracranial hypertension and the intensity of therapy necessary for control of ICP.
描述(由适用提供):尽管进行了预防测量,但创伤性脑损伤(TBI)仍然是儿童死亡和残疾的主要原因。尽管迄今为止,大多数TBI的小儿治疗方案来自成人研究,但没有治疗方案在改善儿童的预后特别成功。在成熟和不成熟的动物中使用中度低温(HYPO)(HYPO)(HYPO)(32-33?c)进行了许多实验室研究,在TBI后为成年患者进行了成功的II和III期临床研究,在TBI后24至48小时,在缺血性脑损伤后进行了多项试验,这些试验支持了这种练习的效率。与严重的残疾相比,最近发表的最新发表的HIE治疗试验在6小时内显示了预后,尤其是死亡率的显着改善。尽管成人中度低调的多中心III期随机对照临床试验(RCT)由于能量而早期停止,但并非缺乏效率,但次级分析确实强调,与老年受试者相比,年轻的成年患者(<40 Y)倾向于改善结果。这一发现以及通过早期冷却(<6 h)改善结局的趋势,导致了资助的降低RCT,特别包括16-45岁的患者和最近开始的疗医院前冷却。根据我们的试验临床试验(PCT)的结果,使用中度降低了儿童的严重TBI,以下应用是多中心III期RCT来确定儿童严重TBI后诱导的早期冷却(6 h)(32-33¿C)是否在儿童身后进行了48小时,并保持48 h的死亡率和在3个MOS后的死亡率相比,与NORM horm hormothermia相比会提高死亡的死亡率(37-38-38-38-38-38-38-38。次要假设再次基于对PCT的分析,是在儿童严重TBI之后的早期低调,并维持48 h:1)将改善全球功能,这将通过GOS/ GOS/ GOS扩展的儿科(GOS-E PED)(GOS-E PED)(GOS-E PED)和神经认知状态在6和12受伤的智力发展,记忆和行为的范围内,在6和12的范围内进行了神经认知状态; 2)与年龄较大的儿童相比,在<6 y的年幼儿童中,> 6岁和3)将更有效,而颅内高血压和控制ICP所需的治疗强度将更少。

项目成果

期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Acute brain injury and therapeutic hypothermia in the PICU: A rehabilitation perspective.
PICU 中的急性脑损伤和治疗性低温:康复视角。
Therapeutic hypothermia decreases phenytoin elimination in children with traumatic brain injury.
  • DOI:
    10.1097/ccm.0b013e318292316c
  • 发表时间:
    2013-10
  • 期刊:
  • 影响因子:
    8.8
  • 作者:
    Empey PE;Velez de Mendizabal N;Bell MJ;Bies RR;Anderson KB;Kochanek PM;Adelson PD;Poloyac SM;Pediatric TBI Consortium: Hypothermia Investigators
  • 通讯作者:
    Pediatric TBI Consortium: Hypothermia Investigators
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

P. David ADELSON其他文献

P. David ADELSON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('P. David ADELSON', 18)}}的其他基金

exRNA signatures Predict Outcomes after brain injury
exRNA 特征预测脑损伤后的结果
  • 批准号:
    8710365
  • 财政年份:
    2013
  • 资助金额:
    $ 20万
  • 项目类别:
exRNA signatures Predict Outcomes after brain injury
exRNA 特征预测脑损伤后的结果
  • 批准号:
    8581741
  • 财政年份:
    2013
  • 资助金额:
    $ 20万
  • 项目类别:
exRNA signatures Predict Outcomes after brain injury
exRNA 特征预测脑损伤后的结果
  • 批准号:
    9128756
  • 财政年份:
    2013
  • 资助金额:
    $ 20万
  • 项目类别:
exRNA signatures Predict Outcomes after brain injury
exRNA 特征预测脑损伤后的结果
  • 批准号:
    9042774
  • 财政年份:
    2013
  • 资助金额:
    $ 20万
  • 项目类别:
Pediatric Traumatic Brain Injury Consortium: Hypothermia
儿科创伤性脑损伤联盟:体温过低
  • 批准号:
    7888182
  • 财政年份:
    2007
  • 资助金额:
    $ 20万
  • 项目类别:
Pediatric Traumatic Brain Injury Consortium: Hypothermia
儿科创伤性脑损伤联盟:体温过低
  • 批准号:
    7198415
  • 财政年份:
    2007
  • 资助金额:
    $ 20万
  • 项目类别:
Pediatric Traumatic Brain Injury Consortium: Hypothermia
儿科创伤性脑损伤联盟:体温过低
  • 批准号:
    7419012
  • 财政年份:
    2007
  • 资助金额:
    $ 20万
  • 项目类别:
Pediatric Traumatic Brain Injury Consortium: Hypothermia
儿科创伤性脑损伤联盟:体温过低
  • 批准号:
    7629754
  • 财政年份:
    2007
  • 资助金额:
    $ 20万
  • 项目类别:
EFFICACY OF HYPOTHERMIA IN PEDIATRIC TBI: HYPOTHERMIA IN THE TREATMENT OF SEVERE
低温治疗小儿 TBI 的疗效:低温治疗严重创伤性脑损伤
  • 批准号:
    7203129
  • 财政年份:
    2005
  • 资助金额:
    $ 20万
  • 项目类别:
EFFICACY OF HYPOTHERMIA IN PEDIATRIC TBI: LOCAL CEREBRAL BIOCHEMICAL SECONDARY
低温治疗小儿 TBI 的疗效:局部脑生化二级
  • 批准号:
    7203130
  • 财政年份:
    2005
  • 资助金额:
    $ 20万
  • 项目类别:

相似国自然基金

自然接触对青少年网络问题行为的作用机制及其干预
  • 批准号:
    72374025
  • 批准年份:
    2023
  • 资助金额:
    40 万元
  • 项目类别:
    面上项目
大气污染物对青少年心理健康的影响机制研究
  • 批准号:
    42377437
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目
心肺耐力对青少年执行功能影响效应及其特定脑区激活状态的多民族研究
  • 批准号:
    82373595
  • 批准年份:
    2023
  • 资助金额:
    47 万元
  • 项目类别:
    面上项目
中国父母情绪教养行为对青少年非自杀性自伤的影响及其机制
  • 批准号:
    32300894
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
执行技能训练联合动机行为治疗对注意缺陷多动障碍青少年疗效及脑机制
  • 批准号:
    82371557
  • 批准年份:
    2023
  • 资助金额:
    65 万元
  • 项目类别:
    面上项目

相似海外基金

Mechanisms of Juvenile Neurogenesis and Post-Stroke Recovery: Determining the Role of Age-Associated Neuroimmune Interactions
青少年神经发生和中风后恢复的机制:确定与年龄相关的神经免疫相互作用的作用
  • 批准号:
    10637874
  • 财政年份:
    2023
  • 资助金额:
    $ 20万
  • 项目类别:
PROgression of Tuberculosis infECTion in young children living with and without HIV: the PROTECT study
感染和未感染艾滋病毒的幼儿结核感染的进展:PROTECT 研究
  • 批准号:
    10641389
  • 财政年份:
    2023
  • 资助金额:
    $ 20万
  • 项目类别:
A Novel VpreB1 Anti-body Drug Conjugate for the Treatment of B-Lineage Acute Lymphoblastic Leukemia/Lymphoma
一种用于治疗 B 系急性淋巴细胞白血病/淋巴瘤的新型 VpreB1 抗体药物偶联物
  • 批准号:
    10651082
  • 财政年份:
    2023
  • 资助金额:
    $ 20万
  • 项目类别:
Preclinical Validation of Personalized Molecular Assays for Measurable Residual Disease Monitoring in Pediatric AML
用于儿科 AML 可测量残留疾病监测的个性化分子检测的临床前验证
  • 批准号:
    10643568
  • 财政年份:
    2023
  • 资助金额:
    $ 20万
  • 项目类别:
Development of practical screening tools to support targeted prevention of early, high-risk drinking substance use
开发实用的筛查工具,以支持有针对性地预防早期高风险饮酒物质的使用
  • 批准号:
    10802793
  • 财政年份:
    2023
  • 资助金额:
    $ 20万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了